Rescue therapy for lamivudine-resistant chronic hepatitis B: Comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 8, 2010, Pages 1374-1380

  Kim, Hong Joo ^a   Park, Jung Ho ^a   Park, Dong Il ^a   Cho, Yong Kyun ^a   Sohn, Chong Il ^a   Jeon, Woo Kyu ^a   Kim, Byung Ik ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

adefovir; entecavir; lamivudine resistant; rescue treatment

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTERMETHOD COMPARISON; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHINOPHARYNGITIS; SEROCONVERSION; SIDE EFFECT; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VIRUS REPLICATION;

EID: 77954914077     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06381.x     Document Type: Article

References (26)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral. Hepat. 2004 11 : 97 107.
2. Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 1997 337 : 1733 1745.
3. Chen C-J, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 295 : 65 73.
4. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006 130 : 678 686.
5. Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003 124 : 105 117.
6. Liaw YF, Leung N, Guan R et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005 25 : 472 489.
7. Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001 33 : 1527 1532.
8. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003 37 : 1309 1319.
9. Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin. Gastroenterol. Hepatol. 2006 4 : 936 962.
10. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 45 : 507 539.
11. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE IV. Crossresistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther. 2005 10 : 625 633.
12. Schiff ER, Lai CL, Hadziyannis S et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003 38 : 1419 1427.
13. Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004 126 : 81 90.
14. Peters MG, Hann HW, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004 126 : 91 101.
15. Shermann M, Yurdaydin C, Simsek H et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008 48 : 99 108.
16. Fung SK, Chae HB, Fontana RJ et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. 2006 44 : 283 290.
17. Yeon JE, Yoo W, Hong SP et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006 55 : 1488 1495.
18. Lee YS, Suh DJ, Lim YS et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006 43 : 1385 1391.
19. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005 42 : 1414 1419.
20. Lee CH, Kim SO, Byun KS et al. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 2006 130 : 1144 1152.
21. Yeon JE, Yoo W, Hong SP et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006 55 : 1488 1495.
22. Shermann M, Yurdaydin C, Sollano J et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006 130 : 2039 2049.
23. Suzuki F, Toyoda J, Katano Y et al. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J. Gastroenterol. Hepatol. 2008 23 : 1320 1326.
24. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007 45 : 307 313.
25. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007 133 : 1445 1451.
26. Yatsuji H, Suzuki F, Sezaki H et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J. Hepatol. 2008 48 : 923 931.